Have a personal or library account? Click to login
Liver Fibrosis: Causes and Methods of Assessment, A Review Cover

Liver Fibrosis: Causes and Methods of Assessment, A Review

Romanian Journal of Internal Medicine
Volume 53 (2015): Issue 4 (December 2015)
By: Ali Erfani Karimzadeh Toosi  
Open Access
|Dec 2015

References

  1. 1. KOH C, HELLER T. Approach to the diagnosis of portal hypertension. THEO HELLER 2012; 1(5): 133-135.10.1002/cld.78649928531186871
    Search in Google Scholar
  2. 2. FLOREANI A, CAZZAGON N, MARTINES D, CAVALLETTO L, BALDO V, CHEMELLO L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Digestive and Liver Disease, Liver, Pancreas and Biliary Tract 2011; 43(11): 887-892.10.1016/j.dld.2011.06.01121783442
    Search in Google Scholar
  3. 3. POUPON R, CORPECHOT C. Elastography-based assessment of primary biliary cirrhosis staging. Digestive and Liver Disease 2011; 3(11): 839-840.10.1016/j.dld.2011.08.00121893435
    Search in Google Scholar
  4. 4. CASTERA L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 291-303.10.1016/j.bpg.2011.02.00321497746
    Search in Google Scholar
  5. 5. CASTERA L, FORNS X, ALBERTI A, et al. Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology 2008; 48(5): 835-847.10.1016/j.jhep.2008.02.00818334275
    Search in Google Scholar
  6. 6. ROCKEY DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008; 134(1): 8-11.10.1053/j.gastro.2007.11.05318166342
    Search in Google Scholar
  7. 7. FORBES SJ, PAROLA M. Liver fibrogenic cells. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 207-217.10.1016/j.bpg.2011.02.00621497739
    Search in Google Scholar
  8. 8. LEE JS, SEMELA D, IREDALE J, SHAH VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007; 45: 817-825.
    Search in Google Scholar
  9. 9. YANG JD, NAKAMURA I, ROBERTS LR. The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Semin Cancer Biol 2012; 21: 35-43.10.1016/j.semcancer.2010.10.007305042820946957
    Search in Google Scholar
  10. 10. ZHAO W, ZHANG L, YIN Z, SU W, REN G, ZHOU C, YOU J, FAN J, WANG X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 2011; 129: 2651-2561.10.1002/ijc.2592021213212
    Search in Google Scholar
  11. 11. KANG N, YAQOOB U, GENG Z, BLOCH K, LIU C, GOMEZ T, BILLADEAU D, et al. Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol 2010; 177: 1888-1900.10.2353/ajpath.2010.100187294728420802179
    Search in Google Scholar
  12. 12. AMANN T, BATAILLE F, SPRUSS T, MUHLBAUER M, GABELE E, SCHOLMERICH J, KIEFER P, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009; 100: 646-653.10.1111/j.1349-7006.2009.01087.x19175606
    Search in Google Scholar
  13. 13. SANCHO-BRU P, JUEZ E, MORENO M, KHURDAYAN V, MORALES-RUIZ M, COLMENERO J, ARROYO V, et al. Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver International 2010; 30: 31-41.10.1111/j.1478-3231.2009.02161.x19929904
    Search in Google Scholar
  14. 14. GUO HB, RANDOLPH M, PIERCE M. Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: Inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase. J Biol Chem 2007; 282: 22150-22162.10.1074/jbc.M61151820017537730
    Search in Google Scholar
  15. 15. SCHLUGER LK, SHEINER PA, THUNG SN, LAU JY, MIN A, WOLF DC, FIEL I, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976.10.1002/hep.5102305058621177
    Search in Google Scholar
  16. 16. BONNARD P, LESCURE FX, AMIEL C, GUILARD SCHMIDT JB, CALLARD P, GHARAKHANIAN S, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14: 806-811.10.1111/j.1365-2893.2007.00874.x17927617
    Search in Google Scholar
  17. 17. DEV A, PATEL K, CONRAD A, BLATTE LM, MC HUTCHISON JG. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2006; 4: 797-801.10.1016/j.cgh.2006.03.01916682255
    Search in Google Scholar
  18. 18. LIU J, ZHANG Z, TU X, LIU J, ZHANG H, ZHANG J, ZANG Y, et al. Knockdown of N-acetylglucosaminyl transferase V ameliorates hepatotoxin-induced liver fibrosis in mice. Toxicol Sci 2013; 135(1): 144-155.10.1093/toxsci/kft13523798564
    Search in Google Scholar
  19. 19. MIAO CG, YANG YY, HE X, HUANG C, HUANG Y, ZHANG L, LV XW, JIN Y, LI J. Wnt signaling in liver fibrosis: progress, challenges and potential directions. Biochimie 2013; 95(12): 2326-2335.10.1016/j.biochi.2013.09.00324036368
    Search in Google Scholar
  20. 20. HAZRA S, XIONG S, WANG J, RIPPE RA, KRISHNA V, CHATTERJEE K, TSUKAMOTO H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004; 279: 11392-11401.10.1074/jbc.M31028420014702344
    Search in Google Scholar
  21. 21. SHE H, XIONG S, HAZRA S, TSUKAMOTO H. Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 2005; 280: 4959-4967.10.1074/jbc.M41007820015537655
    Search in Google Scholar
  22. 22. ZENG G, AWAN F, OTRUBA W, MULLER P, APTE U, TAN X, GANDHI C, et al. Wnt’er in liver: expression of Wnt and frizzled genes in mouse. Hepatology 2007; 45: 195-204.10.1002/hep.2147317187422
    Search in Google Scholar
  23. 23. LEMAIGRE FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology 2009, 137, 1, 62-79.10.1053/j.gastro.2009.03.03519328801
    Search in Google Scholar
  24. 24. THIERY JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15(6): 740-746.10.1016/j.ceb.2003.10.00614644200
    Search in Google Scholar
  25. 25. MEDICI D, NAWSHAD A. Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-κB and LEF-1. Matrix Biol 2010; 29(3):161-165.10.1016/j.matbio.2009.12.003284984520018240
    Search in Google Scholar
  26. 26. SHINTANI Y, MAEDA M, CHAIKA N, JOHNSON KR, WHEELOCK MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-β signaling. Am J Respir Cell Mol Biol 2008; 38: 95-104.10.1165/rcmb.2007-0071OC217613117673689
    Search in Google Scholar
  27. 27. ZHOU BP, DENG J, XIA W, XU J, LI YM, GUNDUZ M, HUNG MC. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931-940.10.1038/ncb117315448698
    Search in Google Scholar
  28. 28. LIANG F, ZHANG S, WANG B, QIU J, WANG Y. Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway. J Mol Histol 2014; 45(2): 141-51.10.1007/s10735-013-9540-524045896
    Search in Google Scholar
  29. 29. XIONG D, LIOU Y, SHU J, LI D, ZHANG L, CHEN J. Down-regulating ribonuclease inhibitor enhances metastasis of bladder cancer cells through regulating epithelial-mesenchymal transition and ILK signaling pathway. Exp Mol Pathol 2014; 96(3): 411-421.10.1016/j.yexmp.2014.04.01224768914
    Search in Google Scholar
  30. 30. YAN Z, YIN H, WANG R, WU D, LIU B, SU Q. Overexpression of integrin-linked kinase (ILK) promotes migration and invasion of colorectal cancer cells by inducing epithelial-mesenchymal transition via NF-κB signaling. Acta Histochem 2014; 116(3): 527-33.10.1016/j.acthis.2013.11.00124360977
    Search in Google Scholar
  31. 31. BATALLER R, ROMBOUTS K, ALTAMIRANO J, MARRA F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 231-244.10.1016/j.bpg.2011.02.01021497741
    Search in Google Scholar
  32. 32. SCHUPPAN D, KREBS A, BAUER M, HAHN EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003: 10 (Suppl 1): S59-67.10.1038/sj.cdd.440116312655347
    Search in Google Scholar
  33. 33. HASELTINE EL, PENNEY MS, GEORGE S, KIEFFER TL. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat 2015, ahead of print.10.1111/jvh.1238225582683
    Search in Google Scholar
  34. 34. FLISIAK R. Chance of hepatic fibrosis treatment in chronic hepatitis C (in Polish). Przegl Epidemiol 2004; 58(Suppl 1): 76-79.
    Search in Google Scholar
  35. 35. LUGO-BARUQUI A, BAUTISTA LÓPEZ CA, Armendáriz-Borunda J. Novel treatments for hepatitis C viral infection and the hepatic fibrosis. Article in Spanish. Rev Med Chil 2009; 137(2): 280-288.
    Search in Google Scholar
  36. 36. PENZ-ÖSTERREICHER M, ÖSTERREICHER CH, TRAUNER M. Fibrosis in Autoimmune and Cholestatic Liver Disease. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 245-258.10.1016/j.bpg.2011.02.001313411221497742
    Search in Google Scholar
  37. 37. ALISI A, DE VITO R, MONTI L, NOBILI V. Liver fibrosis in paediatric liver diseases. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 259-268.10.1016/j.bpg.2011.02.00821497743
    Search in Google Scholar
  38. 38. PINZANI M, ROSSELLI M, ZUCKERMANN M. Liver Cirrhosis. Best Practice & Research Clinical Gastroenterology 2011; 25(2): 281-290.10.1016/j.bpg.2011.02.00921497745
    Search in Google Scholar
  39. 39. PAVLOV CS, CASAZZA G, NIKOLOVA D, TSOCHATZIS E, BURROUGHS AK, IVASHKIN VT, GLUUD C. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 22; 1:CD010542. [Epub ahead of print]10.1002/14651858.CD010542.pub2708174625612182
    Search in Google Scholar
  40. 40. VERGNIOL J, FOUCHER J, TERREBONNE E, BERNARD PH, LE BAIL B, MERROUCHE W, COUZIGOU P, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140(7): 1970-1979.10.1053/j.gastro.2011.02.05821376047
    Search in Google Scholar
  41. 41. SCHIAVON LL, SCHIAVON JLN, CARVALHO-FILHO RJ. Noninvasive means of diagnosing liver fibrosis in hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866.10.3748/wjg.v20.i11.2854396199224659877
    Search in Google Scholar
  42. 42. LIN ZH, XIN YN, DONG QJ, WANG Q, JIANG XJ, ZHAN SH, SUN Y, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53(3): 726-736.10.1002/hep.2410521319189
    Search in Google Scholar
  43. 43. KAYADIBI H, YASAR B, OZKARA S, SERDAR MA, KURDAS OO, GONEN C. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis. Scand J Clin Lab Invest 2014; 74(3): 240-247.10.3109/00365513.2013.87939224460024
    Search in Google Scholar
  44. 44. HOLMBERG SD, LU M, RUPP LB, LAMERATO LE, MOORMAN AC, VIJAYADEVA V, BOSCARINO JA, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013; 57(2): 240-246.10.1093/cid/cit245
    Search in Google Scholar
  45. 45. PAUNOVIC K, STOJANOVIC M, DIMITRIJEVIC Z, PAUNOVIC G, DJORDJEVIC V, KONSTANTINOVIC L, KOSTIC S. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection. Med Arch 2012; 66(4): 226-230.10.5455/medarh.2012.66.226-230
    Search in Google Scholar
  46. 46. SHAHEEN AA, MYERS RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46(3): 912-921.10.1002/hep.21835
    Search in Google Scholar
  47. 47. XIAO G, YANG J, YAN L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis. Hepatology 2015; 61(1): 292-302.10.1002/hep.27382
    Search in Google Scholar
  48. 48. NGUYEN K, PAN C, XIA V, HU J, HU KQ. Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients. J Viral Hepat 2015 Jan 22 [Epub ahead of print].10.1111/jvh.12388
    Search in Google Scholar
  49. 49. XU XY, KONG H, SONG RX, ZHAI YH, WU XF, AI WS, LIU HB. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One 2014; 9(6): e100182.10.1371/journal.pone.0100182
    Search in Google Scholar
  50. 50. POYNARD T, DE LEDINGHEN V, ZARSKI JP, STANCIU C, MUNTEANU M, VERGNIOL J, FRANCE J, et al. Relative performances of FibroTest, FibroScan®, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard. Journal of Hepatology 2012; 56: 541-548.10.1016/j.jhep.2011.08.007
    Search in Google Scholar
  51. 51. MYERS RP, LAYRARGUES GP, KIRSCH R, POLLETT A, BEATON M, LEVSTIK M, DUARTE-ROJO A, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan® XL probe. Journal of Hepatology 2012; 56(3): 564-570.10.1016/j.jhep.2011.10.007
    Search in Google Scholar
  52. 52. PATEL J, PARIKH P, BHATE P, CHOKSEY A, KHOT A, INGLE M, SAWANT P. Correlation of Liver Stiffness Measurement by FibroScan® in Alcoholic Liver Disease and Hepatitis B Related Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2014; 4(2): S74-S79.10.1016/j.jceh.2014.02.143
    Search in Google Scholar
  53. 53. ROUND AM, NAP-HILL E, TAKACH O, LAM EC, KO HH, RAMJI A. Fibrosis Regression in Persons Treated for HBV Utilizing Transient Elastography (FibroScan®). Gastroenterology 2014; 146(5): S-961-S-962.10.1016/S0016-5085(14)63500-9
    Search in Google Scholar
  54. 54. CORPECHOT C, GAOUAR F, EL NAGGAR A, KEMGANG A, WENDUM D, POUPON R, CARRAT F, et al. Liver stiffness assessed by FibroScan® is a major prognostic factor in primary sclerosing choangitis. Journal of Hepatology 2014; 60(1): S34-S44.10.1016/S0168-8278(14)60086-6
    Search in Google Scholar
  55. 55. ERFANI KARIMZADEH TOOSI A. Investigating the severity of liver fibrosis by transient elastography (FibroScan®) in patients receiving methotrexate. A thesis submitted as partial fulfillment for degree of Subspeciality in Adult Gastroenterology and Hepatology. Guilan University of Medical Sciences Dec 2013.
    Search in Google Scholar
  56. 56. MIREEN FRIEDRICH–RUST, MEI–FANG ONG, SWANTJE MARTENS, et al. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. Gastroenterology 2008; 134(4): 960-974.10.1053/j.gastro.2008.01.03418395077
    Search in Google Scholar
  57. 57. TALWALKAR JA, KURTZ DM, SCHOENLEBER SJ, et al. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2007; 5(10): 1214-1220.10.1016/j.cgh.2007.07.02017916549
    Search in Google Scholar
  58. 58. TAPPER EB, CASTERA L, AFDHAL NH. FibroScan® (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clinical Gastroenterology and Hepatology 2015; 13(1): 27-36.10.1016/j.cgh.2014.04.03924909907
    Search in Google Scholar
  59. 59. CASSINOTT C, LAPUYADE B, MOURIES A, HIRIART JB, VERGNIOL J, GAYE D, CASTAIN C, et al. Non-invasive assessment of liver fibrosis with impulse elastography: Comparison of Supersonic Shear Imaging with ARFI and FibroScan®. Journal of Hepatology 2014; 61(3): 550-557.10.1016/j.jhep.2014.04.04424815876
    Search in Google Scholar
  60. 60. CROSS TJS, CALVARUSO V, MAIMONE S, CAREY I, CHANG TP, PLEGUEZUELO M, et al. Prospective comparison of FibroScan®, king’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010; 17(8): 546-554.10.1111/j.1365-2893.2009.01210.x19874477
    Search in Google Scholar
  61. 61. MACALUSO FS, MAIDA M, CAMMÀ C, CABIBBO G, CABIBI D, ALDUINO R, DI MARCO V, et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. Journal of Hepatology 2014; 61(3): 523-529.10.1016/j.jhep.2014.04.04524815874
    Search in Google Scholar
  62. 62. CASTÉRA L, LE BAIL, ROUDOT-THORAVAL F, BERNARD PH, FOUCHER J, MERROUCHE W, COUZIGOU P, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan®) with standard laboratory tests and non-invasive scores. Journal of Hepatology 2009; 50(1): 59-68.10.1016/j.jhep.2008.08.01819013661
    Search in Google Scholar
  63. 63. BOSCH J. Towards the non-invasive diagnosis of cirrhosis: The nuts-cirrhosis connection. Journal of Hepatology 2009; 50(1): 4-6.10.1016/j.jhep.2008.10.01319019481
    Search in Google Scholar
  64. 64. VICTOR DE LÉDINGHEN, JULIEN VERGNIOL, MAYLIS CAPDEPONT, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. Journal of Hepatology 2014; 60(5): 1026-1031.10.1016/j.jhep.2013.12.01824378529
    Search in Google Scholar
  65. 65. BERZIGOTTI A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. Journal of Hepatology 2014; 60(5): 910-912.10.1016/j.jhep.2014.01.01724486330
    Search in Google Scholar
  66. 66. BAVU E, GENNISSON JL, COUADE M, BERCOFF J, MALLET V, FINK M, BADEL A, et al. Non-invasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol 2011; 37(9): 1361-1373.10.1016/j.ultrasmedbio.2011.05.01621775051
    Search in Google Scholar
  67. 67. RESINO S, SÁNCHEZ-CONDE M, BERENGUER J. Coinfection by human immunodeficiency virus and hepatitis C virus: non-invasive assessment and staging of fibrosis. Curr Opin Infect Dis 2012; 25(5): 564-9.10.1097/QCO.0b013e32835635df22744318
    Search in Google Scholar
  68. 68. CASTERA L, WINNOCK M, PAMBRUN E, PARADIS V, PEREZ P, LOKO MA, ASSELINEAU J, et al. Comparison of transient elastography (FibroScan®), FibroTest®, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med 2014; 15(1): 30-9.10.1111/hiv.1208224007567
    Search in Google Scholar
  69. 69. SÁNCHEZ-CONDE M, MONTES-RAMÍREZ ML, MIRALLES P, ALVAREZ JM, BELLÓN JM, RAMÍREZ M, ARRIBAS JR, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with non-invasive serum markers. J Viral Hepat 2010; 17(4): 280-6.10.1111/j.1365-2893.2009.01180.x19732322
    Search in Google Scholar
DOI: https://doi.org/10.1515/rjim-2015-0039 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Journal RSS Feed
Language: English
Page range: 304 - 314
Submitted on: May 5, 2015
|
Published on: Dec 10, 2015
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Liver biopsy,
FibroScan®,
Fibrosis,
Fibrosis mechanism,
Fibrotest
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Cardiology,
Gastroenterology,
Rheumatology

© 2015 Ali Erfani Karimzadeh Toosi, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 53 (2015): Issue 4 (December 2015)Next article